The TMC125-C214 Study Provides Early Access to TMC125 for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens and Will Also Gather Information on the Long-term Safety and Tolerability of TMC125 Combined With Other Antiretroviral Drugs

NCT00354627 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
5178
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Tibotec Pharmaceuticals, Ireland